Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Andersen, S. T.
Right arrow Articles by Vissing, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Andersen, S. T.
Right arrow Articles by Vissing, J.
Related Collections
Right arrow Glycogenoses
Right arrow Muscle disease
Right arrow All Genetics
NEUROLOGY 2006;67:716-718
© 2006 American Academy of Neurology
Brief Communications

Do carriers of PYGM mutations have symptoms of McArdle disease?

Susanne Tvede Andersen, MD, Morten Dunø, PhD, Marianne Schwartz, PhD and John Vissing, MD, PhD

From the Neuromuscular Research Unit, Department of Neurology, and the Copenhagen Muscle Research Center (S.T.A., J.V.); and Department of Clinical Genetics (M.D., M.S.) National University Hospital, Rigshospitalet, Copenhagen, Denmark.

Address correspondence and reprint requests to Dr. John Vissing, Department of Neurology, 2082 National University Hospital, Rigshospitalet Blegdamsvej 9, DK-2100 Copenhagen, Denmark; e-mail: vissing{at}rh.dk

The authors investigated whether carriers of single myophosphorylase gene (PYGM) mutations have symptoms of McArdle disease. They studied the oxidative capacity and lactate responses to maximal cycle exercise in eight patients with McArdle disease, seven single PYGM mutation carriers, and 11 healthy subjects. Heterozygotes had maximal oxidative capacity and peak lactate responses identical to control subjects. Thus, carriers of single PYGM mutations are not prone to develop symptoms of McArdle disease.

Supported by grants from the NOVO Nordic Foundation, the University of Copenhagen, and the Copenhagen Hospital Corporation.

Disclosure: The authors report no conflicts of interest.

Received February 8, 2006. Accepted in final form April 19, 2006.




This article has been cited by other articles:


Home page
 Arch NeurolHome page
S. T. Andersen, R. G. Haller, and J. Vissing
Effect of Oral Sucrose Shortly Before Exercise on Work Capacity in McArdle Disease
Arch Neurol, June 1, 2008; 65(6): 786 - 789.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by AAN Enterprises, Inc.